Etid klinik pou Sipwa nan Iowa
9 etid pou Sipwa ap chèche patisipan nan sit nan Iowa.
Vil nan Iowa
Tèks ofisyèl etid la (Anglè)
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07794579Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- McFarland Clinic PC, Ames
- Midwest Cardiovascular Research Foundation, Davenport
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Des Moines
- ACCOMPLISH-2 Research Site, Iowa City
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Iowa Diabetes and Endocrinology Research Center, West Des Moines
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Iowa Diabetes Research, West Des Moines
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684144A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Ames
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Iowa City
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.